Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction
Abstract As the most malignant tumor, the prognosis of pancreatic cancer is not ideal even in the small number of patients who can undergo radical surgery. As a highly heterogeneous tumor, chemotherapy resistance is a major factor leading to decreased efficacy and postoperative recurrence of pancrea...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-56737-4 |
| _version_ | 1797247280090185728 |
|---|---|
| author | Tianhong Teng Han Shi Yanying Fan Pengfei Guo Jin Zhang Xinyu Qiu Jianghua Feng Heguang Huang |
| author_facet | Tianhong Teng Han Shi Yanying Fan Pengfei Guo Jin Zhang Xinyu Qiu Jianghua Feng Heguang Huang |
| author_sort | Tianhong Teng |
| collection | DOAJ |
| description | Abstract As the most malignant tumor, the prognosis of pancreatic cancer is not ideal even in the small number of patients who can undergo radical surgery. As a highly heterogeneous tumor, chemotherapy resistance is a major factor leading to decreased efficacy and postoperative recurrence of pancreatic cancer. In this study, nuclear magnetic resonance (NMR)-based metabolomics was applied to identify serum metabolic characteristics of pancreatic ductal adenocarcinoma (PDAC) and screen the potential biomarkers for its diagnosis. Metabolic changes of patients with different CA19-9 levels during postoperative chemotherapy were also monitored and compared to identify the differential metabolites that may affect the efficacy of chemotherapy. Finally, 19 potential serum biomarkers were screened to serve the diagnosis of PDAC, and significant metabolic differences between the two CA19-9 stratifications of PDAC were involved in energy metabolism, lipid metabolism, amino acid metabolism, and citric acid metabolism. Enrichment analysis of metabolic pathways revealed six shared pathways by PDAC and chemotherapy such as alanine, aspartate and glutamate metabolism, arginine biosynthesis, glutamine and glutamate metabolism, citrate cycle, pyruvate metabolism, and glycogolysis/gluconeogeneis. The similarity between the metabolic characteristics of PDAC and the metabolic responses to chemotherapy provided a reference for clinical prediction of benefits of postoperative chemotherapy in PDAC patients. |
| first_indexed | 2024-04-24T19:56:11Z |
| format | Article |
| id | doaj.art-9f1f59a915354d5c8080045e732b4dc3 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T19:56:11Z |
| publishDate | 2024-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-9f1f59a915354d5c8080045e732b4dc32024-03-24T12:19:23ZengNature PortfolioScientific Reports2045-23222024-03-0114111210.1038/s41598-024-56737-4Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis predictionTianhong Teng0Han Shi1Yanying Fan2Pengfei Guo3Jin Zhang4Xinyu Qiu5Jianghua Feng6Heguang Huang7Department of General Surgery, Fujian Medical University Union HospitalDepartment of General Surgery, Fujian Medical University Union HospitalFuzhou Children Hospital of Fujian ProvinceDepartment of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance, Xiamen UniversityDepartment of General Surgery, Fujian Medical University Union HospitalDepartment of General Surgery, Fujian Medical University Union HospitalDepartment of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance, Xiamen UniversityDepartment of General Surgery, Fujian Medical University Union HospitalAbstract As the most malignant tumor, the prognosis of pancreatic cancer is not ideal even in the small number of patients who can undergo radical surgery. As a highly heterogeneous tumor, chemotherapy resistance is a major factor leading to decreased efficacy and postoperative recurrence of pancreatic cancer. In this study, nuclear magnetic resonance (NMR)-based metabolomics was applied to identify serum metabolic characteristics of pancreatic ductal adenocarcinoma (PDAC) and screen the potential biomarkers for its diagnosis. Metabolic changes of patients with different CA19-9 levels during postoperative chemotherapy were also monitored and compared to identify the differential metabolites that may affect the efficacy of chemotherapy. Finally, 19 potential serum biomarkers were screened to serve the diagnosis of PDAC, and significant metabolic differences between the two CA19-9 stratifications of PDAC were involved in energy metabolism, lipid metabolism, amino acid metabolism, and citric acid metabolism. Enrichment analysis of metabolic pathways revealed six shared pathways by PDAC and chemotherapy such as alanine, aspartate and glutamate metabolism, arginine biosynthesis, glutamine and glutamate metabolism, citrate cycle, pyruvate metabolism, and glycogolysis/gluconeogeneis. The similarity between the metabolic characteristics of PDAC and the metabolic responses to chemotherapy provided a reference for clinical prediction of benefits of postoperative chemotherapy in PDAC patients.https://doi.org/10.1038/s41598-024-56737-4Pancreatic cancerSerumNuclear magnetic resonanceMetabolomicsChemotherapy |
| spellingShingle | Tianhong Teng Han Shi Yanying Fan Pengfei Guo Jin Zhang Xinyu Qiu Jianghua Feng Heguang Huang Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction Scientific Reports Pancreatic cancer Serum Nuclear magnetic resonance Metabolomics Chemotherapy |
| title | Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction |
| title_full | Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction |
| title_fullStr | Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction |
| title_full_unstemmed | Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction |
| title_short | Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction |
| title_sort | metabolic responses to the occurrence and chemotherapy of pancreatic cancer biomarker identification and prognosis prediction |
| topic | Pancreatic cancer Serum Nuclear magnetic resonance Metabolomics Chemotherapy |
| url | https://doi.org/10.1038/s41598-024-56737-4 |
| work_keys_str_mv | AT tianhongteng metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction AT hanshi metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction AT yanyingfan metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction AT pengfeiguo metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction AT jinzhang metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction AT xinyuqiu metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction AT jianghuafeng metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction AT heguanghuang metabolicresponsestotheoccurrenceandchemotherapyofpancreaticcancerbiomarkeridentificationandprognosisprediction |